Michael J. Thomas

9.6k total citations · 2 hit papers
141 papers, 6.9k citations indexed

About

Michael J. Thomas is a scholar working on Molecular Biology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Michael J. Thomas has authored 141 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 49 papers in Surgery and 33 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Michael J. Thomas's work include Cholesterol and Lipid Metabolism (32 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Peroxisome Proliferator-Activated Receptors (21 papers). Michael J. Thomas is often cited by papers focused on Cholesterol and Lipid Metabolism (32 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Peroxisome Proliferator-Activated Receptors (21 papers). Michael J. Thomas collaborates with scholars based in United States, Germany and France. Michael J. Thomas's co-authors include Mary G. Sorci‐Thomas, Shaila Bhat, John A. Thomas, John S. Parks, J.S. Owen, Peter Rotwein, Michael P. Samuel, Xuewei Zhu, Gwendalyn J. Randolph and Emmanuel L. Gautier and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Michael J. Thomas

136 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

2004 519 citations Michael J. Thomas et al. Journal of Clinical Oncology profile →
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael J. Thomas United States	45	2.7k	1.8k	1.4k	1.3k	1.2k	141	6.9k
Frederick C. de Beer United States	52	3.7k 1.4×	3.3k 1.8×	1.4k 1.1×	1.5k 1.2×	963 0.8×	131	8.3k
Anthony Markham New Zealand	60	2.3k 0.9×	1.4k 0.8×	697 0.5×	783 0.6×	1.8k 1.5×	163	9.3k
Giuseppe Montalto Italy	56	3.7k 1.4×	2.9k 1.6×	1.5k 1.1×	869 0.7×	1.6k 1.4×	346	11.7k
Johannes Oldenburg Germany	67	4.1k 1.5×	985 0.5×	1.1k 0.8×	923 0.7×	865 0.7×	658	18.1k
Leonard Kritharides Australia	49	2.7k 1.0×	3.0k 1.6×	891 0.7×	906 0.7×	752 0.6×	298	8.7k
Victor W. Armstrong Germany	57	2.1k 0.8×	2.5k 1.4×	719 0.5×	530 0.4×	910 0.8×	239	9.8k
Susan Acton United States	22	3.0k 1.1×	2.6k 1.4×	2.3k 1.7×	1.2k 1.0×	810 0.7×	29	8.6k
Elke Schaeffeler Germany	52	2.8k 1.1×	1.4k 0.8×	535 0.4×	754 0.6×	3.3k 2.8×	181	9.6k
Jacobus Burggraaf Netherlands	43	1.4k 0.5×	932 0.5×	795 0.6×	748 0.6×	821 0.7×	274	6.7k
Kari Pulkki Finland	47	2.0k 0.8×	1.2k 0.7×	522 0.4×	742 0.6×	886 0.7×	206	8.0k

Countries citing papers authored by Michael J. Thomas

Since Specialization

Citations

This map shows the geographic impact of Michael J. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Thomas more than expected).

Fields of papers citing papers by Michael J. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Thomas. The network helps show where Michael J. Thomas may publish in the future.

Co-authorship network of co-authors of Michael J. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Thomas. A scholar is included among the top collaborators of Michael J. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Thomas. Michael J. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kriska, Tamás, Anja Herrnreiter, Sandra L. Pfister, et al.. (2024). Cellular metabolism of substance P produces neurokinin-1 receptor peptide agonists with diminished cyclic AMP signaling. American Journal of Physiology-Cell Physiology. 327(1). C151–C167.

Thomas, Michael J., et al.. (2024). PCPE2: Expression of multifunctional extracellular glycoprotein associated with diverse cellular functions. Journal of Lipid Research. 65(11). 100664–100664. 4 indexed citations

Frost, Nikolaj, Annalen Bleckmann, Frank Griesinger, et al.. (2023). Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122). Clinical Lung Cancer. 24(6). 568–572.

Bozorgmehr, Farastuk, Petros Christopoulos, Inn Chung, et al.. (2022). Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial. BMC Cancer. 22(1). 1011–1011. 11 indexed citations

Seed, Clive R., et al.. (2020). Effect of HIV pre‐exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post‐PrEP deferral period. Vox Sanguinis. 116(4). 379–387. 18 indexed citations

Miyazawa, Taiki, Kiyotaka Nakagawa, Sharon Kim, et al.. (2018). Curcumin and piperine supplementation of obese mice under caloric restriction modulates body fat and interleukin-1β. Nutrition & Metabolism. 15(1). 12–12. 39 indexed citations

Vanegas, Sally M, Mohsen Meydani, Junaidah B. Barnett, et al.. (2017). Substituting whole grains for refined grains in a 6-wk randomized trial has a modest effect on gut microbiota and immune and inflammatory markers of healthy adults. American Journal of Clinical Nutrition. 105(3). 635–650. 201 indexed citations

Melchior, John, Ryan G. Walker, Jamie Morris, et al.. (2017). A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state. Nature Structural & Molecular Biology. 24(12). 1093–1099. 52 indexed citations

Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →

10.

Martel, Catherine, Wenjun Li, Brian Fulp, et al.. (2013). Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. Journal of Clinical Investigation. 123(4). 1571–1579. 255 indexed citations

11.

Youm, Yun‐Hee, Thirumala‐Devi Kanneganti, Bolormaa Vandanmagsar, et al.. (2012). The NLRP3 Inflammasome Promotes Age-Related Thymic Demise and Immunosenescence. Cell Reports. 1(1). 56–68. 132 indexed citations

12.

Brigic, A, et al.. (2011). How will health-care organizations meet venous thromboembolism targets?. British Journal of Hospital Medicine. 72(1). 35–38. 3 indexed citations

13.

Zhu, Xuewei, J.S. Owen, Martha D. Wilson, et al.. (2010). Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. Journal of Lipid Research. 51(11). 3196–3206. 275 indexed citations

14.

Witzenrath, Martin, Birgitt Gutbier, J.S. Owen, et al.. (2007). Role of platelet-activating factor in pneumolysin-induced acute lung injury. Critical Care Medicine. 35(7). 1756–1762. 29 indexed citations

15.

Thomas, Michael J.. (2000). Physiological aspects of low-density lipoprotein oxidation. Current Opinion in Lipidology. 11(3). 297–301. 26 indexed citations

16.

Rudel, Lawrence L., et al.. (1998). Lipoprotein and cholesterol metabolism in diet-induced coronary artery atherosclerosis in primates.. Progress in Lipid Research. 37(6). 353–370. 60 indexed citations

17.

Sorci‐Thomas, Mary G., et al.. (1998). The Hydrophobic Face Orientation of Apolipoprotein A-I Amphipathic Helix Domain 143–164 Regulates Lecithin:Cholesterol Acyltransferase Activation. Journal of Biological Chemistry. 273(19). 11776–11782. 64 indexed citations

18.

Rotwein, Peter, Michael J. Thomas, Diane M. Harris, Ann M. Gronowski, & Catherine Le Stunff. (1997). Nuclear Actions of Growth Hormone: An In Vivo Perspective1. Journal of Animal Science. 75. 11–19. 8 indexed citations

19.

Thomas, Michael J., Kiyoshi Kikuchi, David P. Bichell, & Peter Rotwein. (1994). Rapid activation of rat insulin-like growth factor-I gene transcription by growth hormone reveals no alterations in deoxyribonucleic acid-protein interactions within the major promoter.. Endocrinology. 135(4). 1584–1592. 42 indexed citations

20.

Heyll, A., C. Aul, Michael J. Thomas, et al.. (1991). Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates. Annals of Hematology. 63(6). 328–332. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact